Co-creating Value with Stakeholders

To realize the Group’s vision, co-creating value through collaboration and cooperation with a wide range of stakeholders is essential.

From the perspective of delivering value to people facing illness, the Group identifies its key stakeholders. Through the Group’s value chain, we continuously evolve the way we work together with these key stakeholders.

In particular, we believe that in order to continue creating life-changing value that makes people facing illness smile, it is necessary to listen carefully to their voices at various stages of the value chain. This idea is illustrated in the figure.

Under the concept of Patient Centricity, we will create value together with our stakeholders.

Our Key Stakeholders and Communication Opportunities

People facing illness: Patients, caregivers, patient communities、Healthcare professionals. Life-changing value, Patient-centric. Employees: Employees. Engagement, Skills development. Business partners: Partners (suppliers and distributor), Research, Development, and Sales Partners. Equitable business transactions, Co-creation of life-changing value. Capital providers: Shareholders / investors. Increase corporate value, Shareholder returns. Policymakers, industry associations: Central and local governments, Regulators / payers, Industry associations. Improving QOL of patients by providing appropriate medicines, Maintain and improve the public health care system. Community, Environment: Communities, Future generations / environment.Coexisting with local communities, Reducing environmental impact

You can see this table by scrolling horizontally.

Stakeholders	Main communication opportunities and frequency
Patients, caregivers, patient communities	Disease and health information websites	Ongoing
	Medical information contact center	Ongoing
	Patient advocacy activities	Ongoing
Healthcare professionals	Medical websites	Ongoing
	Medical information contact center	Ongoing
	Publication of medical findings in journals and at conferences	Ongoing
	Communication via MR/MSL	Ongoing
Employees	Internal intranet	Ongoing
	Whistleblowing system^*1	Ongoing
	Awards for employees	1 time
	Employee engagement survey	1 time
	Interviews with superiors and team members	Ongoing
	Labor-management talks	Ongoing
Partners (suppliers and distributor)	Supplier briefings	1 time
	Sustainable procurement questionnaire	1 time
	Collaboration on business transactions	Ongoing
Research, development, and sales partners	Partnerships in pharmaceutical research and development	Ongoing
Shareholders / investors	General meeting of shareholders	1 time
	Financial results briefings	4 times
	IR events for R＆D and sustainability topic	3 times
	IR interviews with the CEO	35 times
	IR interviews with management	13 times
	IR interviews by officer in charge of IR	163 times
Central and local governments, regulators / payers, industry associations	Advocacy and collaboration through industry bodies	Ongoing
Communities	Initiatives to support communities	Ongoing
Communities	Dialogue with local residents	Ongoing
Future generations / environment	Initiatives to support communities	Ongoing
Future generations / environment	Climate change response and other environmental measures	Ongoing

*1
The Company has also established a whistleblower system for stakeholders as part of its grievance mechanism.

Links between stakeholders and the value chain

To realize the Group’s vision, co-creating value through collaboration and cooperation with a wide range of stakeholders is essential.

Under the concept of Patient Centricity, we will create value together with our stakeholders.

Initiatives and Industry Associations

Through our involvement in initiatives and industry associations, we understand the demands of our stakeholders and apply them to our group's business activities. In addition, through collaboration with initiatives and industry associations, we will address social issues that are difficult for individual companies to resolve on their own.

Initiatives

Participation as Kyowa Kirin: Task Force on Climate-related Financial Disclosures (TCFD)

World Anti Doping Agency (WADA)

Pharmaceutical Supply Chain Initiative (PSCI)
Participation as the Kirin Group: The United Nations Global Compact^*

RE100

Science Based Targets initiative (SBTi)

*
The Kirin Group, to which our Group belongs, has announced participation in the United Nations Global Compact since September 2005. As a member of the Kirin Group, we observe the 10 principles of the United Nations Global Compact, which address human rights, labor, the environment, and anticorruption

Industry Associations

Japan Business Federation
FPMAJ (The Federation of Pharmaceutical Manufacturers' Associations of JAPAN)
JPMA (Japan Pharmaceutical Manufacturers Association)
PMAT (The Pharmaceutical Manufactureres' Association of Tokyo)